» Articles » PMID: 33844613

Antimicrobial Peptides and Other Peptide-like Therapeutics As Promising Candidates to Combat SARS-CoV-2

Overview
Date 2021 Apr 12
PMID 33844613
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

: There are currently no specific drugs and universal vaccines for Coronavirus disease 2019 (COVID-19), hence urgent effective measures are needed to discover and develop therapeutic agents. Applying peptide therapeutics and their related compounds is a promising strategy to achieve this goal. This review is written based on the literature search using several databases, previous studies, scientific reports, our current knowledge about the antimicrobial peptides (AMPs), and our personal analyses on the potential of the antiviral peptides for the treatment of COVID-19.: In this review, we begin with a brief description of SARS-CoV2 followed by a comprehensive description of antiviral peptides (AVPs) including natural and synthetic AMPs or AVPs and peptidomimetics. Subsequently, the structural features, mechanisms of action, limitations, and therapeutic applications of these peptides are explained.: Regarding the lack and the limitations of drugs against COVID-19, AMPs, AVPs, and other peptide-like compounds such as peptidomimetics have captured the attention of researchers due to their potential antiviral activities. Some of these compounds comprise unique properties and have demonstrated the potential to fight SARS-CoV2, particularly melittin, lactoferrin, enfuvirtide, and rupintrivir that have the potential to enter animal and clinical trials for the treatment of COVID-19.

Citing Articles

Antimicrobial Peptides Against Arboviruses: Mechanisms, Challenges, and Future Directions.

Owliaee I, Khaledian M, Shojaeian A, Madanchi H, Yarani R, Boroujeni A Probiotics Antimicrob Proteins. 2025; .

PMID: 39776036 DOI: 10.1007/s12602-024-10430-0.


The application and prospects of antimicrobial peptides in antiviral therapy.

Yang F, Ma Y Amino Acids. 2024; 56(1):68.

PMID: 39630161 PMC: 11618130. DOI: 10.1007/s00726-024-03427-0.


Antimicrobial peptide-based strategies to overcome antimicrobial resistance.

Girdhar M, Sen A, Nigam A, Oswalia J, Kumar S, Gupta R Arch Microbiol. 2024; 206(10):411.

PMID: 39311963 DOI: 10.1007/s00203-024-04133-x.


Recent advances in the therapeutic potential of cathelicidins.

Guerra M, Vieira B, Calazans A, Destro G, Melo K, Rodrigues E Front Microbiol. 2024; 15:1405760.

PMID: 38989014 PMC: 11233757. DOI: 10.3389/fmicb.2024.1405760.


Enterocin DD14 can inhibit the infection of eukaryotic cells with enveloped viruses.

Teiar R, Sane F, Erol I, Nekoua M, Lecouturier D, Boukherroub R Arch Microbiol. 2024; 206(6):269.

PMID: 38767708 DOI: 10.1007/s00203-024-04002-7.